Daraxonrasib significantly improves survival, disease control, and quality of life in metastatic pancreatic cancer, marking a major advance in targeted second-line treatment options.
Comments
0
Be the first to comment
Sign up now and become a member of the TheBrief.Health community!
Comments
0Be the first to comment
Sign up now and become a member of the TheBrief.Health community!